ADC Therapeutics

January 17, 2018

2017 rewrites the record books as venture funding accelerates

In terms of venture financing, activity in 2017 outpaced that at the height of the biotech boom in 2015, with 68 biotechs attracted rounds of $50m or more.

Asco preview – A second wind for antibody-drug conjugates

2017 rewrites the record books as venture funding accelerates

Ash 2017 preview – Blueprint and Stemline celebrate

Macrogenics and J&J fallout could spell double trouble

Corporate venture firms – dedicated followers of fashion?

ICML roundup – New dogs for old tricks

Interview – With pivotal $105m ADC moves to copy its rivals

Venture treasure bath for oncology, pennies for others

Astra moves to emulate Kadcyla, courtesy of Spirogen

Celtic invests $50m in antibody-drug conjugate start up

Latest Reports

Vantage Pharma, Biotech and Medtech 2018 in Review

Vantage 2019 Preview

Editor's Picks

Array-size deals don’t come around too often

Takeda casts doubt on the remaining approach to amyloidosis

EHA 2019 – Global Blood faces sickle cell questions

Liquid biopsies: the future of cancer diagnosis?

Time to restock big pharma’s leaking pipeline